| Literature DB >> 26318878 |
Brian A McCarthy1, Sophia Yancopoulos1, Mike Tipping2, Xiao-Jie Yan1, Xue Ping Wang1, Fiona Bennett3, Wentian Li1, Martin Lesser1, Santanu Paul1, Erin Boyle1, Carolina Moreno1, Rosa Catera1, Bradley T Messmer4, Giovanna Cutrona5, Manlio Ferrarini6, Jonathan E Kolitz1,7, Steven L Allen1,7, Kanti R Rai1,7, Andrew C Rawstron3, Nicholas Chiorazzi8,9.
Abstract
Chronic lymphocytic leukemia (CLL) is a clonal disease of B lymphocytes manifesting as an absolute lymphocytosis in the blood. However, not all lymphocytoses are leukemic. In addition, first-degree relatives of CLL patients have an ~15 % chance of developing a precursor condition to CLL termed monoclonal B cell lymphocytosis (MBL), and distinguishing CLL and MBL B lymphocytes from normal B cell expansions can be a challenge. Therefore, we selected FMOD, CKAP4, PIK3C2B, LEF1, PFTK1, BCL-2, and GPM6a from a set of genes significantly differentially expressed in microarray analyses that compared CLL cells with normal B lymphocytes and used these to determine whether we could discriminate CLL and MBL cells from B cells of healthy controls. Analysis with receiver operating characteristics and Bayesian relevance determination demonstrated good concordance with all panel genes. Using a random forest classifier, the seven-gene panel reliably distinguished normal polyclonal B cell populations from expression patterns occurring in pre-CLL and CLL B cell populations with an error rate of 2 %. Using Bayesian learning, the expression levels of only two genes, FMOD and PIK3C2B, correctly distinguished 100 % of CLL and MBL cases from normal polyclonal and mono/oligoclonal B lymphocytes. Thus, this study sets forth effective computational approaches that distinguish MBL/CLL from normal B lymphocytes. The findings also support the concept that MBL is a CLL precursor.Entities:
Keywords: B lymphocytes; Chronic lymphocytic leukemia; Diagnosis; Gene expression
Mesh:
Substances:
Year: 2015 PMID: 26318878 DOI: 10.1007/s12026-015-8688-3
Source DB: PubMed Journal: Immunol Res ISSN: 0257-277X Impact factor: 2.829